Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Precigen, Inc.NASDAQ: PGEN
Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026
Other non-cash items growth accelerates
Q2 FY2026 other non-cash items of $10.51M (cash outflow) rose 943.8% year over year, ahead of the +152.1% change in trailing-twelve-month other non-cash items.
Context
- Other non-cash items amounted to 1467.6% of revenue in FY2025, up 414.4 pp from a year earlier.
- Other non-cash items increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +943.8% holds above the trailing-twelve-month pace of +152.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 142.12M USD
- Year-over-year change
- +243.8%
- 4-year CAGR
- +95.6%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 142.12M | +243.8% |
| FY2024 | 2024-12-31 | 41.34M | +1090.3% |
| FY2023 | 2023-12-31 | (4.17M) | +94.7% |
| FY2022 | 2022-12-31 | (78.48M) | -909.0% |
| FY2021 | 2021-12-31 | 9.7M | — |
Other Non-Cash Items vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's LTM Jun 2026 other non-cash items of $100.82M is the 2nd largest of the 8 companies compared; the peer median is $2.08M.
- Its year-over-year change of +152.1% is the 3rd highest of 8, against a peer median of +111.6%.
- Other non-cash items amounts to 117.6% of revenue for PGEN, versus a peer median of 33.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.4M | +609.2% | +204.8% | 1048.1% | |
| LTM Jun 2026 | $100.82M | +152.1% | — | 117.6% | |
| LTM Mar 2026 | $34M | +147.5% | -6.1% | 51.4% | |
| LTM Sep 2026 | $29.31M | -144.5% | +80.0% | 116.4% | |
| LTM Mar 2026 | $12.21M | +224.0% | +15.5% | 13.9% | |
| LTM Mar 2026 | $5.85M | +61.3% | — | 15.1% | |
| LTM Mar 2026 | $5.66M | +90.8% | — | — | |
| LTM Mar 2026 | $2.08M | +111.6% | — | 4.6% | |
| Peer median (excluding PGEN) | $2.08M | +111.6% | +47.8% | 33.3% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| Deferred Income Tax | (167K) | (150K) | (479K) | (1.8M) | 0 |
| Stock-Based Compensation | 13.9M | 10.21M | 9.89M | 9.47M | 10.87M |
| Change in Working Capital | (804K) | (35.7M) | 17.07M | 4.52M | 6.62M |
| Accounts Receivables | (6.56M) | (13.51M) | 12.23M | 414K | (3.2M) |
| Inventory | (1.9M) | 2.34M | 0 | 0 | (9.21M) |
| Accounts Payables | 420K | 379K | (2.42M) | 1.55M | 8.77M |
| Other Working Capital | 7.24M | (24.91M) | 7.26M | 2.56M | 10.26M |
| Other Non-Cash Items | 9.7M | (78.48M) | (4.17M) | 41.34M | 142.12M |
| Operating Cash Flow | (55.77M) | (65.05M) | (66.93M) | (68.17M) | (87.83M) |
| Capital Expenditures | (7.25M) | (4.92M) | (1.54M) | (8.58M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (174.22M) | 0 | (185.03M) | (187.21M) | (208.01M) |
| Sales of Investments | 100.17M | 68.44M | 183.38M | 175.02M | 208.47M |
| Other Investing Activities | 6.76M | 162.9M | 98K | 60K | 0 |
| Investing Cash Flow | (74.54M) | 226.42M | (3.09M) | (20.71M) | (1.54M) |
| Debt Repayment | (466K) | (155.29M) | (43.22M) | 0 | 92.82M |
| Common Stock Issued | 121.05M | 0 | 72.81M | 31.24M | 310K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 608K | 1K | 0 | 346K | (3.08M) |
| Financing Cash Flow | 121.19M | (155.29M) | 29.59M | 110.58M | 90.05M |
| Effect of Forex Changes | 217K | (827K) | (320K) | (27K) | 35K |
| Net Change in Cash | (8.91M) | 5.25M | (40.75M) | 21.67M | 717K |
| Free Cash Flow | (63.02M) | (69.97M) | (68.47M) | (76.76M) | (89.83M) |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.